ATE312911T1 - Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung - Google Patents
Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrungInfo
- Publication number
- ATE312911T1 ATE312911T1 AT99927615T AT99927615T ATE312911T1 AT E312911 T1 ATE312911 T1 AT E312911T1 AT 99927615 T AT99927615 T AT 99927615T AT 99927615 T AT99927615 T AT 99927615T AT E312911 T1 ATE312911 T1 AT E312911T1
- Authority
- AT
- Austria
- Prior art keywords
- antisense oligonucleotides
- present
- neoplastic cell
- treatment
- receptors
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 206010003645 Atopy Diseases 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000005170 neoplastic cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002235420A CA2235420A1 (en) | 1998-06-17 | 1998-06-17 | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| PCT/CA1999/000572 WO1999066037A2 (en) | 1998-06-17 | 1999-06-17 | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE312911T1 true ATE312911T1 (de) | 2005-12-15 |
Family
ID=4162352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99927615T ATE312911T1 (de) | 1998-06-17 | 1999-06-17 | Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6822087B1 (de) |
| EP (1) | EP1088065B1 (de) |
| JP (1) | JP4612188B2 (de) |
| AT (1) | ATE312911T1 (de) |
| AU (1) | AU758447B2 (de) |
| CA (1) | CA2235420A1 (de) |
| DE (1) | DE69928932T2 (de) |
| MX (1) | MXPA00012703A (de) |
| NZ (1) | NZ509308A (de) |
| WO (1) | WO1999066037A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| US6566132B1 (en) * | 2001-04-26 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Interferon gamma receptor 1 expression |
| US7745420B2 (en) * | 2001-07-06 | 2010-06-29 | Topigen Pharmaceutique, Inc. | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| AU2003268032A1 (en) * | 2002-07-29 | 2004-02-16 | Epigenesis Pharmaceuticals, Inc. | Composition and methods for treatment and screening |
| CN1918175A (zh) | 2003-09-29 | 2007-02-21 | 托皮根药品公司 | 治疗包括炎症状况的疾病的寡核苷酸组合物和方法 |
| TW200526777A (en) * | 2003-11-12 | 2005-08-16 | Combinatorx Inc | Combinations for the treatment of proliferative diseases |
| ATE512223T1 (de) * | 2004-04-29 | 2011-06-15 | Univ Yale | Nukleaseresistente externe führungssequenzen zur behandlung von entzündlichen und virusbedingten atemwegserkrankungen |
| MX2007005083A (es) * | 2004-10-29 | 2007-10-03 | Topigen Pharmaceuticals Inc | Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica. |
| JP2008544742A (ja) * | 2005-02-25 | 2008-12-11 | アイシス ファーマシューティカルズ， インコーポレーテッド | ＩＬ４Ｒ−αに対する組成物およびその使用 |
| EP1931804A4 (de) * | 2005-10-03 | 2009-01-21 | Isis Pharmaceuticals Inc | Kombinationstherapie mit budesonid und auf il4-rezeptor-alpha gerichtetem antisense-oligonukleotid |
| US20070270366A1 (en) * | 2005-12-20 | 2007-11-22 | Karras James G | Double stranded nucleic acid molecules targeted to il-4 receptor alpha |
| AU2007252192B2 (en) | 2006-05-19 | 2013-10-17 | Topigen Pharmaceuticals Inc. | Oligonucleotides affecting expression of phosphodiesterases |
| CN102099474B (zh) * | 2008-05-15 | 2014-05-28 | 托皮根药品公司 | 用于治疗炎症和赘生性细胞增殖的寡核苷酸 |
| US8341614B2 (en) * | 2008-06-06 | 2012-12-25 | Apple Inc. | Memory management for closures |
| JP2014502953A (ja) | 2010-08-16 | 2014-02-06 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 細胞透過性治療薬の鼻腔内送達 |
| DK3050574T3 (da) | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
| EP3606525B1 (de) | 2017-04-05 | 2025-12-10 | Alkahest, Inc. | Zusammensetzungen zur behandlung von alterungsassoziierten störungen unter verwendung von ccr3-inhibitoren |
| US12221463B2 (en) | 2020-08-07 | 2025-02-11 | The Board Of Regents Of The University Of Oklahoma | Method of promoting wound healing by inhibiting CCR3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6806061B1 (en) * | 1995-01-19 | 2004-10-19 | Children's Medical Center Corporation | G protein-coupled receptor gene and methods of use therefor |
| US5874211A (en) | 1995-04-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Chemokine expressed in eosinophils |
| FR2734147B1 (fr) | 1995-05-19 | 1997-10-10 | Klein Jean Michel | Dispositif d'osteosynthese implantable |
| FR2735984B1 (fr) | 1995-06-30 | 1997-09-19 | Inst Nat Sante Rech Med | Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic |
| FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
| US6265184B1 (en) | 1995-12-20 | 2001-07-24 | Icos Corporation | Polynucleotides encoding chemokine receptor 88C |
| US6229006B1 (en) | 1995-12-22 | 2001-05-08 | Smithkline Beecham Corporation | Use of antisense oligodeoxynucleotides to produce truncated proteins |
| AUPN780096A0 (en) | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| JP3689118B2 (ja) | 1996-04-26 | 2005-08-31 | メルク エンド カンパニー インコーポレーテッド | 好酸球エオタキシンレセプター |
| EP0906424A2 (de) | 1996-04-26 | 1999-04-07 | Incyte Pharmaceuticals, Inc. | Kombinierte lymphozytrezeptoren (mmlr-ccr), von der chemokin rezeptoren familie |
| KR20010030622A (ko) * | 1997-09-17 | 2001-04-16 | 리차드 알. 이킨 | 다중 표적 하이브리드형성 핵산과 그들의 제조, 구성,제제, 키트 및 응용 |
| CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
-
1998
- 1998-06-17 CA CA002235420A patent/CA2235420A1/en not_active Abandoned
-
1999
- 1999-06-17 JP JP2000554846A patent/JP4612188B2/ja not_active Expired - Fee Related
- 1999-06-17 MX MXPA00012703A patent/MXPA00012703A/es not_active IP Right Cessation
- 1999-06-17 DE DE69928932T patent/DE69928932T2/de not_active Expired - Lifetime
- 1999-06-17 AT AT99927615T patent/ATE312911T1/de not_active IP Right Cessation
- 1999-06-17 US US09/719,737 patent/US6822087B1/en not_active Expired - Lifetime
- 1999-06-17 EP EP99927615A patent/EP1088065B1/de not_active Expired - Lifetime
- 1999-06-17 WO PCT/CA1999/000572 patent/WO1999066037A2/en not_active Ceased
- 1999-06-17 NZ NZ509308A patent/NZ509308A/en not_active IP Right Cessation
- 1999-06-17 AU AU44932/99A patent/AU758447B2/en not_active Ceased
-
2004
- 2004-10-04 US US10/958,204 patent/US7629324B2/en not_active Expired - Fee Related
-
2009
- 2009-10-26 US US12/605,737 patent/US20100286239A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1088065A2 (de) | 2001-04-04 |
| JP4612188B2 (ja) | 2011-01-12 |
| AU4493299A (en) | 2000-01-05 |
| NZ509308A (en) | 2003-05-30 |
| AU758447B2 (en) | 2003-03-20 |
| CA2235420A1 (en) | 1999-12-17 |
| DE69928932D1 (de) | 2006-01-19 |
| MXPA00012703A (es) | 2003-07-14 |
| US7629324B2 (en) | 2009-12-08 |
| JP2002518007A (ja) | 2002-06-25 |
| US20100286239A1 (en) | 2010-11-11 |
| WO1999066037A3 (en) | 2000-04-20 |
| DE69928932T2 (de) | 2006-09-07 |
| WO1999066037A2 (en) | 1999-12-23 |
| US20050282762A1 (en) | 2005-12-22 |
| EP1088065B1 (de) | 2005-12-14 |
| US6822087B1 (en) | 2004-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69928932D1 (de) | Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung | |
| DE60103052D1 (de) | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten | |
| DE69927960D1 (de) | Epiallopregnanolon zur behandlung von krankheiten des cns | |
| ATE377072T1 (de) | Neues gen für eine aminosäure-deacetylase mit spezifität für n-acetyl-l-phosphinothricin, ihre isolierung und verwendung | |
| ATE337780T1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| ATE365042T1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
| DE60223262D1 (de) | Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis | |
| PT1019040E (pt) | Inibicao da actividade de p38-quinase por meio de arilureias | |
| ATE308364T1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
| ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
| DE69828408D1 (de) | Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung | |
| EP2527444A3 (de) | Antisense-Oligonukleotid-Modulation einer STAT3-Expression | |
| FR2854335B1 (fr) | Traitement hors site de catalyseurs d'hydrogenation | |
| DE60234873D1 (de) | Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen | |
| DE69737397D1 (de) | Verwendung von mif-antagonisten zur krebstherapie | |
| ATE404202T1 (de) | Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung | |
| Brzoska et al. | Molecular basis of the α‐MSH/IL‐1 antagonism | |
| ATE222119T1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
| IL152961A0 (en) | Inhibitors of alpha beta 2 mediated cell adhesion | |
| JP2002518007A5 (de) | ||
| AU2672099A (en) | Compositions and methods for wound healing | |
| ATE325341T1 (de) | Zusammenhang zwischen konformation und biologischer aktivität von apoptose-induzierenden phosphodiesteroligonukleotiden | |
| ATE306280T1 (de) | Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen | |
| DE59900286D1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
| DE19681032D2 (de) | Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |